Research output: Contribution to journal › Article › peer-review
Orvinols with mixed kappa/Mu opioid receptor agonist activity. / Greedy, Benjamin M.; Bradbury, Faye; Thomas, Mark P.; Grivas, Konstantinos; Cami-Kobeci, Gerta; Archambeau, Ashley; Bosse, Kelly; Clark, Mary J.; Aceto, Mario; Lewis, John W.; Traynor, John R.; Husbands, Stephen M.
In: Journal of Medicinal Chemistry, Vol. 56, No. 8, 25.04.2013, p. 3207-3216.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Orvinols with mixed kappa/Mu opioid receptor agonist activity
AU - Greedy, Benjamin M.
AU - Bradbury, Faye
AU - Thomas, Mark P.
AU - Grivas, Konstantinos
AU - Cami-Kobeci, Gerta
AU - Archambeau, Ashley
AU - Bosse, Kelly
AU - Clark, Mary J.
AU - Aceto, Mario
AU - Lewis, John W.
AU - Traynor, John R.
AU - Husbands, Stephen M.
N1 - © 2013 American Chemical Society
PY - 2013/4/25
Y1 - 2013/4/25
N2 - Dual-acting kappa opioid receptor (KOR) agonist and mu opioid receptor (MOR) partial agonist ligands have been put forward as potential treatment agents for cocaine and other psychostimulant abuse. Members of the orvinol series of ligands are known for their high binding affinity to both KOR and MOR, but efficacy at the individual receptors has not been thoroughly evaluated. In this study, it is shown that a predictive model for efficacy at KOR can be derived, with efficacy being controlled by the length of the group attached to C20 and by the introduction of branching into the side chain. In vivo evaluation of two ligands with the desired in vitro profile confirms both display KOR, and to a lesser extent MOR, activity in an analgesic assay suggesting that, in this series, in vitro measures of efficacy using the [35S]GTPγS assay are predictive of the in vivo profile.
AB - Dual-acting kappa opioid receptor (KOR) agonist and mu opioid receptor (MOR) partial agonist ligands have been put forward as potential treatment agents for cocaine and other psychostimulant abuse. Members of the orvinol series of ligands are known for their high binding affinity to both KOR and MOR, but efficacy at the individual receptors has not been thoroughly evaluated. In this study, it is shown that a predictive model for efficacy at KOR can be derived, with efficacy being controlled by the length of the group attached to C20 and by the introduction of branching into the side chain. In vivo evaluation of two ligands with the desired in vitro profile confirms both display KOR, and to a lesser extent MOR, activity in an analgesic assay suggesting that, in this series, in vitro measures of efficacy using the [35S]GTPγS assay are predictive of the in vivo profile.
UR - http://www.scopus.com/inward/record.url?scp=84876823658&partnerID=8YFLogxK
U2 - 10.1021/jm301543e
DO - 10.1021/jm301543e
M3 - Article
C2 - 23438330
AN - SCOPUS:84876823658
VL - 56
SP - 3207
EP - 3216
JO - Journal of Medicinal Chemistry
JF - Journal of Medicinal Chemistry
SN - 0022-2623
IS - 8
ER -